May 30, 2018 | Harriet Kozak, Intellus, Rachel Howard, USA, emerging markets
Earlier this month, US President Harriet Kozak and Emerging Markets Director Rachel Howard attended the inaugural Intellus Worldwide Summit in Philadelphia
The theme of the conference was ‘7 billion voices’, exploring how patient experiences, programs and health literacy can be improved through insights delivered by market researchers in the pharmaceutical industry.
As part of the keynote speeches, we were honored to hear the perspective of patient advocates and leaders in rare disease. Hearing directly from patients who had lived through unimaginably challenging experiences provided a humbling reminder and refocusing of our common goal as an industry – to ultimately improve patients’ lives.
Find out more:Â https://www.researchpartnership.com/news/2018/05/intellus-round-up-2018/
This content was provided by Inizio
Latest Content from Inizio
Authored by: Constanza Salas, Jhon Galindo and Rachel Howard
The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry
Authored by: Marc Garcia and Tania Rodrigues
How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.
Living with COPD 2023
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.
With over 20 years’ experience in the industry, Research Partnership Senior Director and market research veteran Andrew Stokes has been appointed Chief Commercial Officer.
Find out how we provided a more holistic understanding of brand equity and a forward indication of potential market share using our advanced analytics solution, Equity AI.
In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.
Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.
